InMed Pharmaceuticals Inc. (INM) · Nov 3, 2026 · Material agreement
$490M merger financing — $490M expected financing; cash runway only into mid-November
InMed’s earnings update keeps the Mentari merger on track, but highlights a thin cash runway and unresolved Nasdaq compliance risk.
InMed is no longer primarily an operating biotech story; it is a cash-constrained vehicle awaiting a reverse merger that would replace its legacy pipeline with Mentari’s migraine-prevention programs. The merger, planned $490 million financing and November 4 shareholder vote were already disclosed before this release, so the filing mainly confirms the existing transition rather than creating a new one.
The strategic pivot is still on schedule, but not completed. InMed continues to target a fourth-quarter 2026 closing, with the combined company expected to operate as Mentari Therapeutics and pursue a new Nasdaq ticker. 〔0〕 The $490 million financing would give the successor company substantial development capital, but that capital is conditional on the transaction closing rather than available to InMed today.
The immediate problem is liquidity, not pipeline progress. Cash fell to $1.0 million from $2.2 million at June 30, while management says available cash funds planned operations only into mid-November. 〔1〕 That creates a narrow bridge between the November 4 vote and the expected closing, leaving little room for delay or additional spending.
Nasdaq has bought the deal more time, not removed the listing risk. InMed’s shareholders’ equity was $1.075 million versus the $2.5 million minimum, and Nasdaq granted until March 15, 2027, to regain compliance. The proposed merger and financing are the intended solution, so the extension helps operationally but does not change the fact that the central fix remains contingent.
| Figure | Q1 FY2027 | Comparison |
|---|---|---|
| R&D expense (Financial Commentary) | $0.2M | $0.6M Q1 FY2026 |
| Cash and equivalents (Financial Commentary) | $1.0M | $2.2M Jun. 30, 2026 |
| Shareholders’ equity (Nasdaq compliance) | $1.075M | $2.5M minimum |
| Expected Mentari financing (Corporate Update) | ~$490M | — |
Bottom line: This is a confirmation of the planned merger path, not a fresh business breakthrough. The financing could reset InMed’s story if the deal closes, but the current company remains financially tight and dependent on that closing happening soon.
Nov. 4 shareholder vote on Mentari merger
A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.
A buy-side analyst on every ticker — the whole market decoded the second it moves, before it's a headline. Free gives you a taste. Pro takes the cap off and opens the full read on every company.
by Signing in NOW, claim your FREE 14-day Pro trial!